The stock of Aquestive Therapeutics Inc (NASDAQ:AQST) last traded at $4.26, up 3.90% from the previous session.
AQST stock price is now 22.05% away from the 50-day moving average and 91.35% away from the 200-day moving average. The market capitalization of the company currently stands at $383.27M.
With the price target of $7, Raymond James recently initiated with Outperform rating for Aquestive Therapeutics Inc (NASDAQ: AQST). , while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, Schobel Alexander Mark, Chief Innovation/Tech Officer sold 50,000 shares of the company’s stock on Mar 15 ’24. The stock was sold for $300,000 at an average price of $6.00. Upon completion of the transaction, the Chief Innovation/Tech Officer now directly owns 984,476 shares in the company, valued at $4.19 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 08 ’24, Chief Innovation/Tech Officer Schobel Alexander Mark sold 25,000 shares of the business’s stock. A total of $129,685 was realized by selling the stock at an average price of $5.19. This leaves the insider owning 1,040,371 shares of the company worth $4.43 million. A total of 6.92% of the company’s stock is owned by insiders.
During the past 12 months, Aquestive Therapeutics Inc has had a low of $0.82 and a high of $6.23. The fifty day moving average price for AQST is $3.5230 and a two-hundred day moving average price translates $2.2372 for the stock.
The latest earnings results from Aquestive Therapeutics Inc (NASDAQ: AQST) was released for Dec, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.12, missing analysts’ expectations of -$0.08 by -0.04. This compares to -$0.20 EPS in the same period last year. The company reported revenue of $13.21 million for the quarter, compared to $10.68 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 23.63 percent. For the current quarter, analysts expect AQST to generate $12.46M in revenue.
